Kura Oncology Inc. (NASDAQ:KURA) is at a critical juncture as it launches its newly approved AML treatment, Komzifti (ziftomenib). The FDA approval drove a 99% stock return, but first-quarter sales missed estimates.
The company is advancing ziftomenib into frontline AML trials, targeting a larger patient population. Barclays Capital maintains an Overweight rating with a $28 price target.
Despite initial commercial challenges, the pipeline and targeted therapy offer significant upside.
SEO Description: Kura Oncology SWOT analysis: FDA approval, early sales results, and future prospects for this biotech stock.
